Omeros Corporation (OMER)
NASDAQ: OMERHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OMER stock chart
Technical analysisKey statistics
All statistics- Market cap
- $983.66M
- P/E (TTM)
- 15.92
- Forward P/E
- 11.95
- EPS (TTM)
- $0.83
- Dividend yield
- None
- 52-week range
- 6.70 – 21.24
- Day range
- 13.07 – 13.88
- Volume / Avg
- 2.02M / 1.36M
- Beta
- —
- Shares outstanding
- 74.46M
52-week range
OMER stock today
Shares of Omeros (OMER) finished lower on Nov 20 at $13.21, a drop of 5.71% or $0.80 per share, versus the S&P 500's 3.70% decline. Shares are 37.8% below their 52-week high of $21.24, set on Sep 22, 2026 and 97.2% above the 52-week low of $6.70, in the middle of the past year's range. OMER is down 23.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 48.9%.
Omeros trades at 15.9x its trailing twelve-month earnings per share of $0.83. Its forward P/E of 12.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Omeros
Company profileOmeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Gregory A. Demopulos M.D.
- Headquarters
- Seattle, WA
- Employees
- 175
- IPO year
- 2009
- Website
- omeros.com
Financial highlights
Full financialsOmeros reported a net loss of $3.4 million, compared with a loss of $156.8 million a year earlier. Diluted earnings per share came in at -$0.05.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-3.35M | $-156.81M | $-117.81M | $47.42M | $194.24M |
| EPS (diluted) | $-0.05 | $-2.70 | $-1.88 | $0.76 | $3.12 |
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$27.50+108.18%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.19 vs $-0.05
- Surprise
- -280.00%
OMER news
All OMER news- Omeros Corporation Reports Third Quarter 2026 Financial ResultsNasdaq
- Omeros expects Q4 2026 discontinued ops income of $5M-$6M while scaling YARTEMLEA education and outpatient useSeeking Alpha
- Why is Omeros stock sliding today?Investing.com
- Omeros Non-GAAP EPS of $0.06 beats by $0.08, revenue of $35.9M misses by $1.37MSeeking Alpha
- Omeros Corporation Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026Business Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPR Newswire
Omeros peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs OMER |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs OMER |
| ANROAlto Neuroscience Inc. | 25.37 | -4.30% | $1.02B | vs OMER |
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs OMER |
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs OMER |
| CTYCity Therapeutics Inc. | 19.32 | +5.29% | $1.03B | vs OMER |
| NKTRNektar Therapeutics | 30.20 | -7.19% | $1.03B | vs OMER |
| JBIOJade Biosciences Inc. | 15.31 | +1.66% | $1.06B | vs OMER |
Indexes, lists and sector
Omeros stock FAQ
What is Omeros's stock price today?
OMER last traded at $13.21 as of Nov 20, 4:00 PM EST, down 5.71% on the day. Prices are delayed at least 15 minutes.
What is OMER's P/E ratio?
OMER trades at a trailing P/E ratio of 15.92 and a forward P/E of 11.95.
Who is Omeros's CEO?
Dr. Gregory A. Demopulos M.D. is the chief executive officer of Omeros Corporation, which has about 175 employees.
What is the OMER 52-week high?
The 52-week high for OMER is $21.24 and the 52-week low is $6.70. The stock is currently 37.8% below its high.